Retatrutide Prescribed Online to North Dakota Residents

Medical Weight Loss Treatment in North Dakota

Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).

Key Benefits

• Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
• Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
• ~58% hepatic fat reduction in Phase 2 sub-group analyses
• Elevated basal metabolic rate via glucagon receptor agonism
• Research-grade purity ≥98% with full CoA, HPLC, and MS documentation

Who is a Good Candidate?

Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.

Available for research use

Serving North Dakota

North Dakota's wide-open spaces and extreme seasons demand healthcare that comes to you. OmniRx Health serves the entire Peace Garden State—from the oil fields of the Bakken to the farms of the Red River Valley, the university towns of Fargo and Grand Forks to the tribal communities of the west. When winter storms make travel impossible or your nearest specialist is hours away, our telehealth platform ensures you still have access to expert medical care.

OmniRx Health providers are licensed by the North Dakota State Board of Medical Examiners for statewide telehealth services.

North Dakota pharmacies in Fargo, Bismarck, Grand Forks, and throughout rural communities provide prescription services with reliable delivery.

North Dakota has progressive telehealth laws designed to serve its dispersed population across the northern plains.

North Dakota insurers cover telehealth services, recognizing virtual care's importance in serving the state's rural population.

Frequently Asked Questions

What is retatrutide and how does it work?

Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).

How does retatrutide compare to semaglutide and tirzepatide in research?

Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.

Is retatrutide available for human use?

No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.

Is telehealth legal in North Dakota?

Yes, North Dakota fully supports telehealth with laws designed to serve its rural population. Licensed providers can offer comprehensive virtual care including prescriptions.

Can Bakken workers use telehealth?

Telehealth is perfect for North Dakota's energy workers, providing convenient care access during busy work schedules and in remote locations.

How does telehealth work during North Dakota winters?

Telehealth eliminates the need to travel during dangerous winter conditions. When roads are impassable, you can still connect with our providers from home.